Because FDA marketing clearance to sell a drug or device in the US remains the brass ring for medical manufacturers around the world, companies consistently invested in US trials in spite of rising costs. By 2016, however, more manufacturers were […]
Introducing SanaCurrents Introducing SanaCurrents, a research service for the serious and sophisticated biotech investor. Founder of SanaCurrents, Bill Langbein, finally brings his service to the mainstream to enable biotech investors to track catalysts through the lens of varying levels of […]
This content is for members only
We all want to be happy, so why are we so drawn to negative and bad news and why does it stir something up inside of us? Is it because bad news is an obstacle to our happiness, and we […]
ARMO Biosciences (ARMO) listed in January 2018 at $17 per share. The company had a phase III pancreatic cancer drug in AMO010, a recombinant form of human interleukin 10 (IL-10). There is no effective drug to treat pancreatic cancer. AMO010 […]
Eiger Biopharmaceuticals (NASDAQ:EIGR), a company developing treatment for rare diseases, which often are reimbursed at a premium price, published a study on April 24, 2018, indicating the effectiveness of its drug, lonafarnib, to treat Hutchinson-Gilford Progeria Syndrome (HGPS). The disease […]
MyoKardia (NASDAQ:MYOK), a leading precision cardiovascular medicine company, reported good data during 2015-16 on its drug, mavacamten, to treat hypertrophic cardiomyopathy (HCM), a condition that reduces the rate of heart contractions because of the thickening of surrounding heart muscles. Mavacamten, […]
Dynavax’s (NASDAQ:DVAX) BLA application for its Hepatitis B vaccine first received a complete response letter from the FDA in 2013 and then experienced further regulatory delays between 2015-2016. Some of the FDA requests involved the vaccine’s overall immunogenicity data, while […]